ClinicalTrials.gg
CompletedNCT03100630Updated Aug 7, 2019

Compare Bioavailability of RO7239361 After Subcutaneous Injection

A Phase 1 interventional study of RO7239361 in Healthy, sponsored by Hoffmann-La Roche. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-07.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Oct 2017, 9 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Randomized study in healthy men and women. Assess the similarity of RO7239361 when injected into the arm, thigh, or the stomach. Collect data on safety of RO7239361.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participant as determined by no significant deviations in normal medical and surgical history and assessments
  • 18 kg/m2 to 32 kg/m2
  • females must be of non-

Exclusion criteria

Exclusion Criteria:

  • tattoos or other skin findings on any of the potential injection sites
  • history of chronic muscle pain within 30 days prior to study treatment
  • prior history of IgG1 therapy

Other protocol defined inclusion and exclusion criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
99 participants (actual)

Study arms

  • Active comparator
    Treatment A: RO7239361

    RO7239361 subcutaneous injections on specified days; abdomen

    Drug: RO7239361

  • Active comparator
    Treatment B: RO7239361

    RO7239361 subcutaneous injections on specified days; arm

    Drug: RO7239361

  • Active comparator
    Treatment C: RO7239361

    RO7239361 subcutaneous injections on specified days; thigh

    Drug: RO7239361

Interventions

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Maximum observed serum concentration (Cmax)

    Time frame: Up to 92 days

  2. AUC from time zero to time of last quantifiable concentration [AUC(0-T)]

    Time frame: Up to 92 days

  3. AUC from time zero extrapolated to infinite time [AUC(INF)]

    Time frame: Up to 92 days

Secondary outcomes

  1. Incidence of Adverse Events ( AEs)

    Time frame: Up to 92 days

  2. Incidence of Serious Adverse Events (SAEs)

    Time frame: Up to 92 days

  3. Change from baseline in electrocardiogram findings

    Time frame: Up to 92 days

  4. Change from baseline in physical examination findings

    Time frame: Up to 92 days

  5. Change from baseline in clinical laboratory test findings

    Time frame: Up to 92 days

07

Study locations

1 site
  • WCCT Global, Inc.
    Cypress, California 90630, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2017 to primary completion in Oct 2017, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2017
First posted
Apr 4, 2017
StartActual
May 9, 2017
Primary completionActual
Oct 17, 2017
CompletionActual
Oct 17, 2017
Last update
Aug 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03100630
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 4, 2017
Start date
May 9, 2017
Primary completion
Oct 17, 2017
Completion
Oct 17, 2017
Last update
Aug 7, 2019

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Taldefgrobep alfa

Start the discussion